EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and validation of a radiogenomics prognostic model integrating PET/CT radiomics and glucose metabolism-related gene signatures for non-small cell lung cancer

Chunsheng Wang, Congjie Wang, Jianguo Zhang, Mingjun Ding, Yizhi Ge, Xia He

European Journal of Nuclear Medicine and Molecular Imaging · 2025-11 · 52 (13) · 4924-4938

DOI: 10.1007/s00259-025-07354-4 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 27.05.2025. Verfasst von Chunsheng Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Affiliated Cancer Hospital of Nanjing Medical Unive…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Positron Emission Tomography Computed Tomography, Lung Neoplasms, Glucose. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Spark Youth Cultivation Program of Jiangsu Cancer Hospital, National Natural Science Foundation of China, Nanjing Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Non-small cell lung cancer (NSCLC) is a highly heterogeneous malignancy characterized by altered glucose metabolism. Integration of PET/CT radiomics with glucose metabolism-related genomic signatures could provide a more comprehensive approach for prognosis and treatment guidance. METHODS: Radiomics features were extracted from PET/CT images of 156 NSCLC patients from The Cancer Imaging Archive (TCIA) database, and glucose metabolism-related gene signatures were obtained from TCGA and GEO databases. We developed a multimodal radiogenomics prognostic model (RGC-score) using least absolute shrinkage and selection operator (LASSO) regression, combining PET/CT radiomics, glucose metabolism-related genes (GMR-genes). Functional enrichment analysis, immune infiltration assessment, and drug sensitivity analysis were performed to investigate the biological significance of glucose metabolism-related genes (GMR-genes). RESULTS: The RGC-score model effectively stratified NSCLC patients into distinct high- and low-risk groups with significant differences in survival outcomes (P < 0.001), demonstrating excellent predictive performance (1-year AUC = 0.907, 5-year AUC = 0.968).GMR-genes are mainly involved in the process of metabolic remodeling of tumors, which is closely related to the immune microenvironment (especially CD8+ T cell infiltration) and immune checkpoint molecule expression. Additionally, significant differences in drug sensitivity were identified between glucose metabolism subtypes. CONCLUSION: The RGC-score robustly predicts NSCLC prognosis and informs metabolic-immune interactions for personalized therapy. Limitations include the retrospective design and modest validation cohort size, necessitating prospective multicenter trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungPositron Emission Tomography Computed TomographyLung NeoplasmsGlucoseHumansPrognosisMaleFemaleMiddle AgedAgedRadiomics

Stichwörter der Autor:innen

Glucose metabolismImmune infiltrationNSCLCPET/CTRadiogenomics

Substanzen

Glucose

Autor:innen und Institutionen

  • Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China.
  • Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 211116, Jiangsu, China.
  • Department of Pulmonary and Critical Care Medicine, Yantai Yuhuangding Hospital, Yantai, 264000, Shandong, China.
  • Department of Pulmonary Oncology, Hubei Key Laboratory of Tumor Biological Behavior, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, Hubei, China.
  • Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, 210009, Jiangsu, China. yzgoncology@163.com.
  • Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 211116, Jiangsu, China. yzgoncology@163.com.

Förderung

  • Spark Youth Cultivation Program of Jiangsu Cancer Hospital
  • National Natural Science Foundation of China
  • Nanjing Science and Technology Plan Project

Zitieren

APA

Wang, C., Wang, C., Zhang, J., Ding, M., Ge, Y., & He, X. (2025). Development and validation of a radiogenomics prognostic model integrating PET/CT radiomics and glucose metabolism-related gene signatures for non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 52(13), 4924-4938. https://doi.org/10.1007/s00259-025-07354-4

Vancouver

Wang C, Wang C, Zhang J, Ding M, Ge Y, He X. Development and validation of a radiogenomics prognostic model integrating PET/CT radiomics and glucose metabolism-related gene signatures for non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2025;52(13):4924-4938. doi:10.1007/s00259-025-07354-4

BibTeX
@article{Wang2025,
  author = {Wang, Chunsheng and Wang, Congjie and Zhang, Jianguo and Ding, Mingjun and Ge, Yizhi and He, Xia},
  title = {Development and validation of a radiogenomics prognostic model integrating PET/CT radiomics and glucose metabolism-related gene signatures for non-small cell lung cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  volume = {52},
  number = {13},
  pages = {4924--4938},
  doi = {10.1007/s00259-025-07354-4}
}
Kostenlos starten →